Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679140 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
A Phase 3 study of COVID-19, SARS-CoV-2 Infection, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,330
- Enrollment target
- 20
- Study locations
NCT06679140 is a Phase 3 study of COVID-19, SARS-CoV-2 Infection that is actively recruiting participants, run by Pfizer. The registered enrollment target is 2,330 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06679140, a Phase 3 study of COVID-19, SARS-CoV-2 Infection, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ibuzatrelvir
Study Locations (20)
California
- National Institute of Clinical Research - Bakersfield - Bakersfield
- 310 Clinical Research - Inglewood
- Long Beach Research Institute - Long Beach
- Long Beach Clinical Trials - Long Beach
- Downtown L.A. Research Center, Inc. - Los Angeles
- Clinica mi Salud by Focil Med - Oxnard
- FOMAT Medical Research - Oxnard
- Paradigm Clinical Research, LLC - Redding
- Acclaim Clinical Research - San Diego
- Tweedy Medical Group - Charity Health - South Gate
- Breathe Clear Institute for Sinus and Allergy Relief - Torrance
Florida
- Innovative Research of West Florida - Clearwater
- Invictus Clinical Research Group - Coconut Creek
- Hillcrest Medical Research LLC - DeLand
- Hillcrest Medical Research - DeLand
- Universal Axon Clinical Research, LLC - Doral
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- Emerson Clinical Research Institute - Washington D.C.
Arkansas
- Applied Research Center of Arkansas - Little Rock
Colorado
- Paradigm Clinical Research, LLC - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,330 participants |
| Start Date | 2024-12-08 |
| Est. Completion | 2028-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679140
The ClinicalTrials.gov registry entry for NCT06679140 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19, SARS-CoV-2 Infection appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06679140 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06679140 about?
NCT06679140 is a clinical study titled "A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease". The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatre...
What is the current status of trial NCT06679140?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,330 participants. The study started on 2024-12-08. Estimated completion is 2028-03-02.
What conditions does trial NCT06679140 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2 Infection.
What interventions are being tested in trial NCT06679140?
The interventions under investigation include: placebo (DRUG), ibuzatrelvir (DRUG).
Who is sponsoring clinical trial NCT06679140?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679140 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19, SARS-CoV-2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.